Atara Biotherapeutics Inc., a leader in T-cell immunotherapy, has announced the pricing of a $16 million offering involving 834,237 shares of its common stock at $6.61 per share, along with pre-funded warrants to purchase 1,587,108 shares priced at $6.6099 per pre-funded warrant. These securities are being offered to a select group of existing institutional investors, including entities affiliated with Adiumentum Capital Management, EcoR1 Capital, Panacea Venture, and Redmile Group. The gross proceeds from this offering are expected to be $16 million, which Atara plans to use primarily to fund activities required for the biologics license application approval for tab-cel, as well as for working capital and general corporate purposes. TD Cowen is serving as the sole bookrunner for this offering.